Past and Future. Current Drugs Targeting HIV-1 Integrase and Reverse Transcriptase-Associated Ribonuclease H Activity: Single and Dual Active Site Inhibitors

Abstract

Catalytic HIV type-1 (HIV-1) integrase (IN) and ribonuclease H (RNase H) domains belong to the polynucleotidyl transferase superfamily and are characterized by highly conserved motifs that coordinate two divalent Mg²⁺ cations and are attractive targets for new antiviral agents. Several structural features of both domains are now available. Drugs targeting the HIV-1 IN are currently approved for anti-HIV therapy, while no drug targeting the HIV-1 RNase H function is yet available. This review describes HIV-1 IN and the RNase H function and structures, compounds targeting their active sites and dual inhibition as a new approach for drug development.

Introduction

HIV type-1 (HIV-1) integrase (IN) and reverse transcriptase (RT)-associated ribonuclease H (RNase H) domains belong to the polynucleotidyl transferase superfamily and share common structural features. The catalytic sites of both enzymes contain a central core composed of three highly conserved amino acid residues forming the DDE motif or RNase H-like fold (Asp, Asp and Glu) [1]. These residues are essential for both enzymatic activities and their mutation leads to catalytic inactivation. Structurally, the core domain is formed by five-strand β sheets in both enzymes and four-to-six α-helices in HIV-1 IN and RNase H, respectively. The five strands of the HIV-1 IN β sheets super-impose closely with the corresponding HIV-1 RNase H sheets (Figure 1A and 1B) [2,3]. However, comparison of the helical regions shows several distinguishing features: IN α1 is displaced from the four β sheet by approximately 6 Å relative to the RNase H α1; IN α2 is a one-turn helix while RNase H α2 is a the three-turn helix; α3 is similarly positioned in both structures; α4 orientation is similar in the two structures, aligned parallel to β1; and in the HIV-1 IN structure, there are two additional helices that are not present in RNase H. IN α5 consists of residues 171–186 and is located adjacent and parallel to β3, whereas α6 extends in residues 196–208, is located on the same side as α1 and has an orientation of approximately 90° with respect to α5. Divalent metal ions and various metals, including Mn²⁺ and Mg²⁺, which are essential for the activity, have been observed in close proximity to active site residues [4].

Figure 1.

Crystallographic structures of the catalytic core domain of HIV-1 IN and RNase H

Currently, >25 different antiretrovirals have been licensed by the US Food and Drug Administration (FDA). The present therapeutic regimen, HAART, is composed of a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) to which a third agent is added. As the third agent, a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor can be chosen. Effective inhibition of viral replication can be achieved in >90% of patients starting with such regimens. Despite such a large armamentarium, both acute and chronic toxicities limit the prolonged use of several antiretroviral agents, and this is even more a concern when patients become older and suffer from age-related comorbidities, as many HIV-negative subjects do. In addition, the selection of drug-resistant strains and the spreading of such strains in newly infected patients is also an increasing concern. Because HIV-1 IN inhibitors (INIs) are expected to retain efficacy against HIV-1 strains resistant to other classes of antiretroviral drugs, they represent a valid second-line therapy. In fact, many INIs with different chemical scaffolds have been developed. Compound (N-{2-[4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl] propan-2-yl}-5-methyl1,3,4-oxadiazole-2-carboxamide; raltegravir [RAL]; 1; Figure 2) is the first inhibitor approved by the FDA in 2007 and has positively affected AIDS therapy [5,6]. Compound 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4 dihydroquinoline-3-carboxylic acid (elvitegravir [EVG]; 2; Figure 2), has been recently approved by the FDA for use in the therapy of HIV-1-infected treatment-naive adults [5,6], while compound 5-hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8adiaza-anthracene-7-carboxylic acid-2,4-difluorobenzylamide (dolultegravir [DTG]; 3; Figure 2) is a second-generation agent currently in Phase III clinical trials [5 –7]. In contrast, no drug targeting the HIV-1 RT-associated RNase H function is available for therapy or is currently in clinical trials [8 –10].

Overall, therefore, there is still a pressing need for the development of novel antiretroviral agents, particularly with new modes of action. Among the novel approaches aimed to identify new HIV-1 inhibitors, the development of dual-action inhibitors, single drugs that may act on two different enzymes, is mostly attractive for the possibility of reducing the number of administered drugs, reducing their chronic toxicity, maintaining the same efficacy and reducing the rapid selection of drug resistance virus strains having a higher resistance barrier. This review briefly describes the HIV-1 IN and the RNase H structures and functions as well as the compounds targeting the active sites of these enzymes. The key mechanism of action of these compounds is the ability to sequester the two divalent cations of the catalytic core, thereby inhibiting the enzymatic activity. In addition, because the two active sites share significant homologies, dual-acting inhibitors are described as new approach for HIV-1 drug development.

HIV-1 integrase: Structure and function

The HIV-1 double-stranded DNA (dsDNA) proviral integration into the chromosomal host cell is an essential step for viral replication that is carried out by the viral coded IN. HIV-1 IN is a 32 kDa protein of 288 amino acids composed of three functional domains: the N-terminal domain (amino acids 1–49), the catalytic core domain (amino acids 50–212) and the C-terminal domain (amino acids 213–288). The active form of the HIV-1 IN is a multimer [11]. Dimerization is required for the 3′-processing step, with tetrameric IN catalysing the strand-transfer reaction [12,13]. Dimeric models were built to reflect the specific contacts between IN and the viral long terminal repeat terminal CA/TG nucleotides identified in vitro [14,15]. During the viral infection, IN operates within large nucleoprotein assemblies, in a complex named the pre-integration complex, which is a macromolecular assemblage consisting of viral DNA, viral proteins and probably host cell proteins. After the pre-integration complex transits into the nucleus, chromatin gets involved through protein–protein as well as DNA–protein interactions, completing the integration process [16,17]. Among the implicated cellular factors is the human lens epithelium-derived growth factor (LEDGF)/p75, a nuclear protein that promotes IN chromatin linkage by allowing specific interaction between its IN-binding domain, represented by residues 347–429 at the C-terminal region of the p75 protein and the IN dimer [18].

Figure 2.

Chemical structures of first-generation and approved HIV type-1 integrase inhibitors

The HIV-1 IN N-terminal domain is characterized by a highly conserved zinc-binding H₁₂H₁₆C₄₀C₄₃ motif [19,20] involved in stabilizing the protein folding and allowing proper IN multimerization [21 –23]. The catalytic core domain contains the catalytic D₆₄D₁₁₆E₁₅₂ motif, highly conserved in all retroviral INs [19]. In addition to its indispensable role in the IN enzymatic activity, it contains functional elements and specific residues that are essential in mediating the integration complex nuclear import [24]. In fact, several residues, such as L102, A128, A129, W132, E170, T174, M178 and I365, as well as the K₁₈₆R₁₈₇K₁₈₈ multimerization motif at the dimer:dimer interface [25 –29], are involved in chemical bonding and in hydrophobic contacts with LEDGF/p75 [26,27] and show an indispensable role in IN nuclear distribution, essential for viral replication [23]. The IN C-terminal domain possesses a strong non-specific DNA-binding ability and is bound to both viral and cellular DNA with its minimal non-specific DNA binding region (amino acids 220–270) [30 –33]. This domain is also involved in protein oligomerization, in some interactions with the HIV-1 RT [31] and LEDGF/p75 [30 –33].

The multimer form of HIV-1 IN accomplishes the viral DNA integration process through a defined set of cutting (termed 3′-processing) and joining (termed strand-transfer) reactions. During 3′-processing, two conserved nucleotides are removed from each 3′-end of the long terminal repeat terminus of the viral DNA obtained at completion of the reverse transcription process. The 3′-processing reaction is carried out in the cytoplasm within the pre-integration complex [34]. After the pre-integration complex is transported through the nuclear pore into the nucleus, the second catalytic step can take place. The strand-transfer reaction catalyses the covalent ligation of the viral dsDNA into the host genome, leading to HIV-1 genome integration. The gap filling at the interfaces between viral and host DNA is then completed using the host DNA repair machinery via a mechanism that is not yet fully understood [35,36].

Although full-length HIV-1 IN has not been crystallized, individual IN domain or two domain fragments have been solved. The model deposited in the Protein Data Bank (PDB; 3OY9), represents two chains, A and B, including the catalytic core domain and the C-terminal domain IN fragments [28,37]. Structural snapshots of the integration process have been recently revealed by a series of crystal structures of the prototype foamy virus (PFV) IN, which is structurally closely related to HIV IN [37]. The first reported structures were those of a PFV IN intasome (a complex of the enzyme with two ends of the viral dsDNA after the 3′-end processing step). In this structure the protein is a tetramer (dimer of dimers) with inner subunits performing the catalysis, outer subunits with disordered N-terminal and C-terminal domains probably playing a structural role, and the DNA ends buried within the IN tetramer and their recessed 3′-ends located at the active sites. Figure 3A shows the PFV IN catalytic D₁₂₈D₁₈₅E₂₂₁ motif within the IN catalytic core [37].

Figure 3.

Schematic representation of prototype foamy virus integrase and HIV-1 reverse transcriptase active sites

HIV-1 RT-associated RNase H activity: Structure and function

The single-stranded RNA (ssRNA) HIV-1 genome ret-rotranscription into proviral dsDNA is an essential step for viral replication that is carried out by the viral coded RT, a multifunctional protein that catalyses different reactions among which are the RNA- and DNA-dependent DNA polymerase and RNase H activities, both essential for viral replication [38]. Structurally, HIV-1 RT is a heterodimer composed of two different subunits, the p66 (66 kDa) and the p51 (51 kDa), deriving from the Pol polyprotein processing by the viral protease [38]. The p66 subunit is arranged into two spatially distinct domains, polymerase and RNase H domains. The polymerase domain shows a characteristic highly conserved structure that resembles a right hand, consisting of fingers (amino acids 1–85 and 118–155), palm (amino acids 86–117 and 156–237) and thumb (amino acids 238–318) subdomains. This subunit also comprises the connection subdomain (residues 319–426) and the RNase H domain (residues 427–560) [39,40]. The p51 subunit lacks the RNase H domain, it does not present enzymatic activities but anchors the proper folding of the p66 subunit that performs all catalytic functions.

The HIV-1 RT-associated RNase H function is essential for virus replication (RNase H-deficient viruses are non-infectious) [9], and it is located at C-terminus of the p66 subunit, 60 Å far from the polymerase active site, equivalent to 17 nucleotides of a DNA:DNA duplex and/or 18 nucleotides of a RNA:DNA hybrid [41]. The RNase H domain catalyses the selective hydrolysis of the RNA strand of the RNA:DNA replication intermediate by a phosphoryl transfer through nucleophilic substitution reactions on phosphate ester. This action occurs through the deprotonation of a water molecule, with the production of a nucleophilic hydroxide group that attacks the scissile phosphate group on the RNA previously activated by coordination with the Mg²⁺ cofactor [42]. The RNase H cleavage specificity for the RNA portion of the RNA:DNA hybrid mainly relies on its particular minor groove width and its interaction with the ‘primer grip’ [38].

The RNase H active site contains a highly conserved, essential, DDE motif comprising the carboxylate residues D443, E478, D498 and D549 (Figure 3B) [3], which coordinate two divalent cations, consistent with the proposed phosphoryl transfer geometry [43].

Integrase inhibitors

In order to design INIs, both the unbound IN protein (3′-processing inhibitors) and the complex resulting from the IN association to viral DNA (strand-transfer inhibitors) have been considered viable strategies [44].

First-generation integrase inhibitors

Random chemical library screening resulted in the initial discovery of INIs. In 2000, Merck Pharmaceuticals identified a class of compounds that contain a diketo acid (DKAs) moiety and their derivatives were shown to inhibit HIV-1 IN by chelation of bound cations [44,45]. The chemical structures of DKAs and their derivatives comprise a common β-diketopropyl linker and different aromatic as well as acid portions. The DKA moiety is the key pharmacophore for enzyme inhibition and the aromatic group improves potency and selectivity of the compounds. Among analogues in which pyrrole groups were conjugated to the phenyl groups, the 4-[1-(4-fluorobenzyl)-1h-pyrrol-2-yl]-2,4-dioxobutanoic acid (L-731,988; 4; Figure 2) was able to block both IN strand-transfer and 3′-processing reactions with 50% inhibitory concentration (IC₅₀) values of 80 nM and 6 μM, respectively [46], whereas the 4-[3,5-bis(phenylmethoxy)phenyl]-2,4-dioxobutanoic acid (L-708,906; 5; Figure 2) exhibited the remarkable property of being selective for strand-transfer (IC₅₀ value of 0.42 μM). Both compounds, L-731,988 (4) and L-708,906 (5), were able to inhibit viral replication in cell culture (50% effective concentration [EC₅₀] of 0.5 and 5.5 μM, respectively) [46,47]. A 5-CITEP structurally related molecule, 1-(5-[4-Fluorobenzyl]furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3-yl)propene (S-1360; 6; Figure 2), was the first strand-transfer inhibitor to enter clinical trials. S-1360 (6) showed favourable pharmacokinetic properties in animal studies, and in 2001 a Phase I/II study was initiated with initial favourable results [48]. However the development of this molecule was discontinued [49].

Integrase inhibitors that are approved and under clinical trial evaluation

The new phase in the INIs development came from the discovery of the naphthyridine derivatives by Merck Pharmaceuticals in which the carboxylate group was replaced with a suitable heterocycle which contained lone pair donor atoms such as an 8-hydroxy-1,6-naphthyridine linked to a benzoyl substituent [49]. The N′-{7-[(4-fluorophenyl)methylcarbamoyl]-8-hydroxy-1,6-naphthyridin-5-yl}-N,N,N′-trimethyloxamide (L-870,812; 7; Figure 2) was one of the most extensively characterized compounds of this series that showed an IC₅₀ value of 40 nM and suppressed retroviral replication in vivo with a 95% effective concentration (EC₉₅) value of 250 nM [47,50]. The derivatization the lead compound L-870,812 (7) led to the development of an oxadiazole with three heteroatoms, raltegravir (1; Figure 2), that inhibited viral replication in cell-based assays with a 95% inhibitory concentration value of 31 nM and ended to be the first INI approved in 2007 by the FDA for clinical therapy [50].

The molecular basis of the action of a number of raltegravir derivatives was revealed through studies of their crystal structure in complex with the PFV intasome (PDB: 3L2V; Figure 4A) [51]. The pharmacophore comprises a rigid ring system with three oxygen or nitrogen atoms spaced to coordinate two metal ions at the active site. Indeed, as shown by crystal structures, these INIs act by blocking the active site and displacing the 3′-end of the viral DNA (Figure 4B). The second common element of raltegravir derivatives is a halogenated benzyl group. The benzyl ring and the ring system with ion-coordinating heteroatoms stack with the penultimate and last bases in the 3′-end of the viral DNA. Since raltegravir clinical approval in 2007, HIV-1 raltegravir-resistant strains emerged indicating three resistance pathways: Q148H/R/K combined with 138K or G140S; N155H along with L74M, E92Q and Q163R; and Y143R/C [52,53].

Figure 4.

Representation of complex prototype foamy virus intasome and raltegravir

Researchers at Japan Tobacco Company provided an alternative DKA motif, the 4-quinolone-3-carboxylic acid motif with the coplanar monoketo acid motif in 4-quinolone-3-carboxylic acids and reported elvitegravir (2; Figure 2) [54]. Elvitegravir has been shown to inhibit HIV-1 IN in vitro with an IC₅₀ value of 7 nM and HIV-1 replication in cell-based assays with an EC₅₀ value of 1.7 nM [54]. Elvitegravir shares with raltegravir a moderate barrier to resistance and the two compounds show some cross-resistance. The raltegravir-associated mutations N155H, Q148H/R/K and G140A/C/S were also selected by elvitegravir [55], therefore precluding the use of eviltegravir for the treatment of most raltegravir-resistant viruses. Differently, the raltegravir-associated mutations Y143C/R/H were not selected by elvitegravir, and HIV-1 bearing these mutations remained susceptible to elvitegravir. Notably, elvitegravir treatment also selected S147G and T66I mutations and F121Y, S153Y and R263K mutations, accessory mutations associated to T66I following elvitegravir treatment, that were not associated to raltegravir-resistance [56].

Shinogi in a collaboration with GlaxoSmithKline designed a different naphthyridinone scaffold as IN active site inhibitors that might be effective on raltegravir-resistant strains and can be considered as second-generation INIs [57]. Among them, dolultegravir (3; Figure 2) has been shown to inhibit the HIV-1 IN with an IC₅₀ value of 7 nM and the HIV-1 replication in cell-based assays with an EC₅₀ value of 1.7 nM [52]. Currently, dolultegravir is in Phase III clinical trial and resistance data suggest that it may have a resistance profile different from the ones shown by raltegravir and elvitegravir, without apparent cross-resistance. Exposure to dolutegravir in selection studies can cause moderate changes in the viral genome at positions E92, L101, T124, S153 and G193 [57]. However no major resistance mutations against dolutegravir have been identified thus far. Because the accumulation of multiple mutations is required to result in a fold-change, it seems that this compound possesses a higher genetic barrier than raltegravir and elvitegravir. In vitro selection experiments revealed R263K, followed by H51Y, as the most common mutation to emerge [57]. The high genetic barrier for dolutegravir resistance is due to tighter binding with IN compared with the first-generation INIs. Furthermore, it has been demonstrated that dolutegravir has a longer dissociative half-life from the IN enzyme than either raltegravir or elvitegravir [57].

Also in the search for second-generation INIs that might display novel patterns of resistance allowing their use in patients who have failed therapy with raltegravir or elvitegravir, Merck Pharmaceuticals optimized another series of INIs starting from the prototype compound tricyclic 10-hydroxy-7,8-dihydropyrazinopyrrolopyrazine-1,9-dione and leading to the identification of (6S)-2-[(3-chloro-4-fluorophenyl) methyl]-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-6,7-dihydropyrazino [5,6]pyrrolo [1,3 b]pyridazine-4-carboxamide (MK-2048; 8; Figure 2) that showed in cell culture assays EC₅₀ values of 1.9, 3.8 and 1.2 nM when tested on wild-type-, raltegravir- and elvitegravir-resistant HIV-1 strains, respectively [58 –60]. Unfortunately, the MK-2048 clinical development had been limited by its poor pharmacokinetic profile.

Furthermore, the search for other second-generation INIs effective on first-generation drug resistance strains led to the identification of a number of new chemical scaffolds, among which the most interesting are the following.

Integrase inhibitors in preclinical development

Dihydroxypyrimidine-4-carboxamides known as HCV NS5B RNA polymerase inhibitors were identified as potent INIs [61]. Several modifications of this scaffold have been explored and led to the synthesis of N-benzyl-5,6-dihydroxy-2-(thiophen-2-yl)pyrimidine-4-carboxamide (9; Figure 5), which inhibits the HIV-1 IN strand transfer reaction with an IC₅₀ value of 80 nM. However, compound 9 showed a reduced ability to inhibit HIV-1 replication in cell-based assays with an EC₅₀ value of 5 μM [62,63]. Further structure–activity studies explored modifications with various acyclic amines and led to the synthesis of 2-[2-(dimethylamino)propan-2-yl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide (10; Figure 5), which inhibits the IN strand transfer reaction with an IC₅₀ value of 0.05 μM and has an EC₉₅ value of 0.06 μM in antiviral assay [62]. Interestingly, compound 10 showed good pharmacokinetic profile and oral bioavailability with moderately low clearance [63].

Figure 5.

Chemical structure of HIV type-1 integrase inhibitors

The pyrrolinone moiety has been identified as a novel scaffold for suitable replacement of the DKA pharmacophore. Similar to DKAs, substituted pyrrolinones also incorporate three heteroatoms for chelating the metal ion in the IN active site. In addition, the pyrrolinone ring structure enforces coplanarity of the heteroatoms, which is believed to be important for metal chelation. Several pyrrolinones with various substitutions were identified through pharmacophore searching [64]. In particular, the compound 5-(3-chlorophenyl)-3-hydroxy-1-(4-methoxyphenethyl)-4-(pyrimidine-2-carbonyl)-1H-pyrrol-2(5H)-one (11; Figure 5), presenting a pyridine substitution, inhibited the IN 3′-processing and the strand transfer reactions with an IC₅₀ value of 77 μM and 40 μM, respectively, and inhibited the viral replication with an unexpected EC₅₀ value of 0.317 μM and a selective index of 83 [65]. Other compounds with the pyrrolidinedione scaffolds were identified as potential HIV-1 INI [53,66] and a library of pyrrolidinedione derivatives was tested in in vitro assay, with the 3-(benzylcarbamoyl)-4-hydroxy-5-oxo-1H-pyrrole-1,2(2H,5H)-dicarboxylic acid derivatives (12; Figure 5), which showed an IC₅₀ value of 0.04 μM [66].

Also tetracyclines have been shown to be a good scaffold for the synthesis of new INIs. In particular, the aryl piperazine derivatives displayed moderate potency against HIV-1 IN and antiviral activity, while being relatively non-cytotoxic with derivative 7-(4-{2-[(4S, 12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamido]ethyl}piperazin-1-yl)-1-ethyl-6,8-difluoro-4-oxo-1,2,3,4-tetrahydroquinolinone-3-carboxylic acid (13), which inhibited IN 3′-processing and strand transfer activities with IC₅₀ values of 20 and 18 μM, respectively (Figure 5) [67].

The pharmacophore properties of styrylquinoline derivatives are well known and were used to design INIs which are equally potent against both 3′-processing and strand transfer reactions [68 –70]. Notably, differently from most INIs, which are non-selective against one of the two IN reactions, several styrylquinolines inhibited HIV-1 replication in cell-based assays at low micromolar concentrations. In particular, (E)-2-(2,3-dihydroxystyryl)-8-hydroxyquinoline-7-carboxylic acid (14; Figure 5) in which the phenyl nucleus is 2,3-dihydroxylated inhibited both the 3′-processing and strand transfer activity with IC₅₀ values of 0.6 and 0.03 μM, respectively, and showed an EC₅₀ value of 1.5 μM [71].

Bicyclic 6,7-dihydroxyoxoisoindolin-1-one-based INIs revealed good potency and strand transfer selectivity in the presence of Mg²⁺ cofactor [72]. Importantly, the introduction of sulfonamide groups in the 4-position led to derivative 2-(3-chloro-4-fluorobenzyl)-6,7-dihydroxy-4-(morpholinosulfonyl)isoindolin-1-one (15; Figure 5), which inhibited the 3′-processing and strand transfer reactions at IC₅₀ values of 6.8 and 0.047 μM, respectively, viral replication with an EC₅₀ value of 2.2 μM, and was more potent than raltegravir against the clinically relevant Y143R IN mutant [73].

Further drug design and structure activity relationship studies led to compounds of the 3-aroyl-2,3-dihydro-1,1-dioxo-1,4,2-benzodithiazine class in which the replacement of the benzodithiazine ring in position 7 with a methyl group determined different inhibitory outcomes, whereas partial hydrogenation led to a significant improvement in activity [74]. For example, the hydrogenated derivative (16; Figure 5) inhibited 3′-processing and strand transfer reactions with IC₅₀ values of 4 and 3 μM, respectively. Interestingly, when assayed on the Y99S and J114A IN mutants the benzodithiazine analogue was fivefold more potent on the latter mutant, pointing to the possibility that amino acid residue Y99 could be involved into compound interaction with IN.

Various substituted pyranones have been previously reported to exhibit anticancer, antimicrobial, anti-coagulant and anti-HIV-protease properties [75,76]. The class of substituted analogues of 3-acetyl-4-hydroxy-pyranone and their difluoridoborate complexes showed potent IN inhibitory effect. In particular, the difluoridoborate complex compound (17; Figure 5) was the most active analogue with IC₅₀ values of 9 and 3 μM for 3′-processing and strand transfer inhibition, respectively [77].

Computational modelling predicted that compounds possessing a pyrazolone scaffold could be an IN pharmacophoric model and these compounds were shown to inhibit the IN catalytic activities [78]. This scaffold had been modified in three sites. In particular, modification of the benzylidene ring of the pyrazolone increased the binding affinity to the metal ion into the IN active site leading to derivative (Z)-1-(3-bromophenyl)-4-[3-(4-fluorobenzyl)-4-methoxybenzylidene]-3-(trifluoromethyl)-1H-pyrazol-5(4H)-one (18; Figure 5), which inhibited the 3′-processing and the strand transfer reactions with IC₅₀ values of 21 and 11 μM, respectively [78].

Recently, tricyclic hydroxy-1H-pyrrolopyridine-tri-ones were reported as scaffolds for INIs [79]. Of note, the analogue methyl 3-[2-(3-chloro-4-fluorobenzyl)-7-hydroxy-5-isopropyl-1,3,6-trioxo-2,3,5,6-tetrahydro-1H-pyrrolo(3,4-c)pyridine-4-yl]propanoate (19; Figure 5) inhibited the strand transfer reaction with an IC₅₀ value of 7.1 μM and the viral replication in cell culture with an EC₅₀ value of 9.2 μM. Of note, compound 19 inhibited Y143R and N155H as well as double mutant G140S/Q148H HIV-1 INIs resistant mutant strains [79].

A series of HIV-1 INIs containing a novel metal binding motif consisting of oxadiazole and triazole substituted naphthyridines were also reported. The design of the key structural components was based on a two-metal coordination pharmacophore [80]. In the 4-nitrobenzofuroxan derivative (20; Figure 5), the presence of the methyl group led to good antiviral activity. In fact, compound 20 inhibited both wild type and raltegravir-resistant mutant IN activities with IC₅₀ values of 0.4–0.5 μM [81].

A series of new hydroxylated 2-arylnaphthalenes also showed good antiviral properties [82]. Notably, the 7-(3,4,5-trihydroxyphenyl) naphthalene-1,2,3-triol analogue was shown to be sensitive to oxidation thus leading to the dimer 4-[2,6-dihydroxy-4-(6,7,8-trihydroxynaphtalen-2yl)phenoxy]-3-hydroxy-7-(3,4,5-trihydroxyphenyl) naphthalene-1,2-dione derivative (21; Figure 5), which inhibited the 3′-processing and the strand transfer reactions with IC₅₀ values of 0.45 and 0.17 μM, respectively, and the HIV-1 replication with an EC₅₀ value of 1.15 μM [82].

Dual integrase and RNase H inhibitors

The above described structural features shared by HIV-1 IN and RNase H led to the hypothesis that compounds that inhibited IN and/or other polynucleotidyl transferase enzymes could also act on RNase H and focused attention on the development of molecules that could be capable of dual IN/RNase H inhibition as a new approach that may reduce the number of drugs administered to HIV-positive patients, decrease the selection of drug-resistant strains and diminish drug toxicity.

The identification of compound 2-hydroxy-4H-isoquinoline-1,3-dione (22; Figure 6), an endonuclease-dependent influenza polymerase inhibitor with a metal dependent mechanism of action, led to a pharmacophore model consisting of three oxygen atoms able to mimic the interactions between substrate, nucleophile and the leaving group oxygens in the transition state of the influenza virus endonuclease active site [83]. Given that the two metal ion mechanism of catalysis is also used by HIV-1 RNase H, the prototype N-hydroxyimide (compound 22) was tested on the HIV-1 RNase H and found to inhibit it with an IC₅₀ value of 0.6–1 μM [84]. Accordingly, compound 22 did not inhibit the Escherichia coli RNase H activity (which has a one metal ion mechanism of catalysis), showed lower potency against the HIV-1 RT-associated RNA-dependent DNA polymerase (RDDP) activity (IC₅₀ value of 41 μM), and was reported to form co-crystals with the isolated HIV-1 RNase H domain in a strictly metal dependent mode [83 –85]. While, to the best of our knowledge, no report on the effects of compound 22 on HIV-1 IN have been published, compound 22 derivatives variously substituted in position 7 of the isoquinoline ring were reported to be dual HIV-1 RNase H and INIs, even though they were cytotoxic and did not inhibit viral replication [86]. A second series of compound 22 analogues variously substituted in position 4 of the isoquinoline ring by alkyl and arylalkyl chains was also published, with some compounds showing dual inhibition and some selectively active on HIV-1 IN, but always unable to inhibit viral replication due to their cytotoxic effects [87].

Figure 6.

Chemical structures of dual HIV type-1 integrase and ribonuclease H inhibitors

As described above, compounds previously reported to inhibit both influenza virus endonuclease and HIV-1 IN were DKAs [44,88]. Consequently, DKA derivative 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid (BTDBA; 23; Figure 6) was shown to inhibit both HIV-1 RNase H and IN activities with IC₅₀ values of 3.2 and 1.9 μM, respectively, while it was inactive on the E. coli RNase H and on HIV replication in cell culture [89]. Biochemical and modelling studies confirmed the interaction of the DKA group with the metal ions in the HIV RNase H active site, with the benzoylamide moiety that was proposed to extend towards the W266, L422 and W426 amino acid residues on the p51 subunit [89 –91]. Starting from a parallel screening aimed at the identification of other HIV-1 INIs [92,93], the DKA derivative 6-[1-(4-fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl ester (RDS 1643; 24; Figure 6) was shown to inhibit the HIV-1 RNase H and IN activities with an IC₅₀ value of 13 and 90 μM, respectively [94]. RDS 1643 (24) did not inhibit the RT-associated RDDP activity and the avian myeloblastosis virus (AMV) and E. coli RNase H activities, while it inhibited both wild-type and NNRTI-resistant HIV-1 strain replication with EC₅₀ values of 7–14 μM and a selective index of 5. Biochemical studies confirmed that RDS 1643 is able to chelate the metal ions in the RNase H catalytic site [94].

A high-throughput screening of a National Cancer Institute library of pure natural products led to the identification of compounds 2,7-dihydroxy-4–1(methylethyl)-2,4,6-cycloheptatrien-1-one (β-thujaplicinol, 25; Figure 6) and 1,2,3,4-tetrahydro-5–7-dihydroxy-9-methyl-2-(1-methylethenyl)-6H-benzocyclohepten-6-one (manicol, 26; Figure 6), which were reported to inhibit both HIV-1 RNase H activity with IC₅₀ values of 0.2 and 60 μM, respectively, and IN strand transfer reaction with IC₅₀ values of 21 and 71 μM, respectively [95,96]. β-Thujaplicinol (25) also inhibited HIV-2, E. coli and human RNase H activities with IC₅₀ values of 0.77, 50 and 5.7 μM, respectively, while manicol (26) inhibited HIV-2 and human RNase H activities with IC₅₀ values of 1.7 and 3.5 μM, respectively. While both compounds were not able to inhibit HIV-1 RDDP activity [97], following biochemical and crystal studies they were proposed to: coordinate the divalent cations in the RNase H active site [97,98]; interact with the Y501 residue of the RNase H primer grip forming π-stacking interactions with the central tropolone ring of β-thujaplicinol (25) [97]; form ionic or hydrogen bond interactions with the side chains of the RNase H domain residues E478, D498, H539 and D549; and chelate the metal ions in the IN active site [96,98]. A series of mono-substituted and di-substituted, 3,7-dihydroxytropolones were shown to inhibit both HIV-1 RNase H and RDDP functions, as well as both HIV-1 IN 3′-processing and strand transfer activities, in the low micromolar range [99]. The most potent derivative, the 4-monosubstituted 3,7-dihydroxytropolone (SP47, 27; Figure 6) inhibited HIV-1 RT and IN catalytic activities with IC₅₀ values in the 0.7–2.3 μM range. Interestingly, also the HIV-1 RDDP was reported to be very sensitive to magnesium concentration and it was proposed that the binding of Mg²⁺ ions in the DP catalytic site is required for compound binding. 3,7-Dihydroxytropolones, however, were found to be cytotoxic and therefore devoid of antiviral activity in cell culture [99].

The naphthyridine pharmacophore was initially reported to be important in INI development, also involving divalent ions coordination [100] and it was subsequently reported to inhibit also the HIV-1 RNase H activity [101]. The naphthyridine derivative ethyl 1,4-dihydroxy-2-oxo-1,2,3,4-tetrahydroquinoline-3-carboxylate (MK1; 28; Figure 6), in fact, was reported to inhibit HIV-1 RNase H activities with an IC₅₀ value of 0.11 μM and HIV-1 replication with an EC₅₀ value of 2.8 μM, and was not cytotoxic at the 50 μM concentration [101]. Further structure–activity studies led to compound 4-{[4′-(aminomethyl)-(1,1′-biphenyl)-4-yl] methyl}-1-hydroxy-1,8-naphthyridin-2(1H)-one (29; Figure 6) that inhibited the HIV-1 RNase H and IN activities with IC₅₀ values of 45 nM and 24 μM, respectively [102]. Compound 29 also inhibited HIV-1 RDDP activity with an IC₅₀ value of 24 μM and the replication of wild-type as well as INI-resistant HIV-1 strains with an EC₅₀ value of 0.19 μM, showing a selective index of 17. However, it was inactive in multi-cycle viral replication assays due to high toxicity [102].

Pyrimidinol carboxylic acids were reported to be stable HIV INIs that effectively mimic the α,γ-DKAs and α,γ-DK amides units [62] and their scaffold was used also for the synthesis of HIV-1 RNase H inhibitors [103]. In particular, 2-(3,4-dichlorobenzyl)-5,6-dihydroxypyrimidine-4-carboxylic acid (30; Figure 6) inhibited the HIV-1 RNase H activity with an IC₅₀ value of 1.2 μM. Biochemical and crystallographic studies confirmed its metal dependent mode of action [103,104]. None of these pyrimidinol carboxylic acids, however, inhibited HIV-1 replication, possibly due to insufficient intrinsic potency, low cell permeability or high protein binding [103].

RNase H inhibitors

Following the identification of the first DKAs as HIV-1 IN and RNase H inhibitors [89,94], a few other classes of compounds were identified as selective HIV-1 RNase H inhibitors.

5-nitro-furan-2-carboxylic acid carbamoylmethyl ester (NAMCE) derivatives were identified in a screening of small molecular weight compounds [105]. Compound 5-nitro-furan-2-carboxylic acid adamantan-1-carbamoylmethyl ester (31; Figure 7) inhibited the HIV-1 RNase H activity with an IC₅₀ value of 30 μM, having no effect on HIV-1 RT-associated RDDP and IN activities as well as E. coli RNase H activity [105]. In silico studies suggested that compound 31 nitrofuran group chelates the metal ions in the RNase H active site, while its carbonyl oxygen atom in the amide group may interact with the side chain of S553 residue and its adamantan group can make hydrophobic contacts with the side chain of K550 residue [105]. Three series of NAMCE analogues were subsequently synthesized, among which compound 2-[(4-acetoxybenzyl)(tert-butyl)amino]-2-oxoethyl 5-nitrofuran-2-carboxylate (32; Figure 7) was able to inhibit HIV-1 RNase H with an IC₅₀ value of 0.9 μM [106]. Molecular modelling studies performed on these analogues further suggested that NAMCE derivatives bind at the RNase H active site with their oxygen atoms, and are supposed to be strongly coordinated to divalent metal ions [106].

Figure 7.

Chemical structure of HIV type-1 ribonuclease H inhibitors

By contrast with the previously described N-hydroxyimide derivatives [84,86,87], a recent series of substituted 3-hydroxyquinolin-2(1H)-ones was reported to selectively inhibit the HIV-1 RNase H in the low micromolar range while inactive on IN [107]. Compound N-(4-fluorobenzyl)-3-hydroxy-2-oxo-1,2-dihydroquinoline-4-carboxamide (33; Figure 7) was reported to inhibit the HIV-1 RNase H activity with an IC₅₀ value of 19 μM, while it was not able to inhibit both HIV-1 RDDP and IN activities, chelating the metal ions in the RNase H catalytic site [107]. Compound 33, however, did not inhibit viral replication due to its cytotoxicity (50% cytotoxic concentration [CC₅₀]=29 μM).

Thiocarbamates and triazoles were reported to inhibit the HIV-1 RNase H activity [108]. In fact, the thiocarbamate derivatives compound 2-[(2,4-dichlorophenyl) amino]-2-oxoethyl dibenzylcarbamodithioate (34; Figure 7) was effective on HIV-1 RNase H activity with an IC₅₀ value of 5 μM, while it was ineffective on HIV-1 RDDP and E. coli RNase H [108]. The triazole derivative compound 4-benzyl-3-(benzylthio)-5-(thiophen-2-yl)-4H-1,2,4-triazole (35; Figure 7) was effective on HIV-1 RNase H and RDDP activities with IC₅₀ values of <2 and 27 μM, respectively, while it was ineffective on E. coli RNase H. Notably, both compounds 34 and 35 inhibited the viral replication with EC₅₀ values of 1.3 and 4 μM, respectively. However, while time of addition studies confirmed that they act at the level of RT-associated functions, no data on their effect on HIV-1 IN has been reported [108].

Conclusions

In conclusion, after the approval of INIs for treatment of HIV-1 infections, several screenings were performed aimed at the development of second-generation INIs that may be effective on mutant HIV-1 strains resistant to the first-generation INIs. In addition, given the structural similarities between IN and RNase H active sites, a number of attempts have been made to identify compounds that may act on both enzymes. The identification and characterization of the molecular determinants that are essential for the interaction between the inhibitors and both IN and RNase H active site will be needed in order to be able to rationally develop compounds that may be truly dual inhibitors. This dual approach is certainly a valid rationale for drug development and a deeper understanding of differences and similarities between the two active sites will be of help to discover new potent HIV-1 inhibitors. In this regard it is of note that, recently, the crystal structure of the complex of HIV-1 RT, an NNRTI and an RNA/DNA hybrid was reported [109]. This is particularly important because, while >20 RT structures with nucleic acid substrate have been reported, only this structure contains an RNA/DNA hybrid. Hence, this information may be very useful for further studies aimed to determine how HIV-1 RNase H selects and binds its substrate and consequently it may open new avenues for identifying novel anti-HIV drug targets [109].

Footnotes

Acknowledgements

This work was supported by RAS grant LR 7/2007 CRP-24915 and MIUR PRIN 2010.

The authors declare no competing interests.

References

Nowotny

. Retroviral integrase superfamily: The structural perspective. EMBO Rep 2009; 10:144–151.

Goldgur

Dyda

Hickman

Jenkins

Craigie

Davies

. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc Natl Acad Sci U S A 1998; 95:9150–9154.

Peletskaya

Kogon

Tuske

Arnold

Hughes

. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA. J Virol 2004; 78:3387–3397.

Dyda

Hickman

Jenkins

. Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases. Science 1994; 266:1981–1986.

Grinsztejn

Nguyen

Katlama

. Safety and efficacy of the HIV-1 integrase inhibitor raltegavir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A Phase II randomized controlled trial. Lancet 2007; 369:1261–1269.

Sato

Motomura

Aramati

. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006; 49:1506–1508.

Xue

Jin

Ning

. Exploring the molecular mechanism of cross-resistence to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. J Chem Inf Model 2013; 53:210–222.

Tramontano

. HIV-1 RNase H: Recent progress in an exciting, yet little explored, drug target. Mini Rev Med Chem 2006; 6:727–737.

Tramontano

Di Santo

. HIV-1 RT-associated RNase H function inhibitors: Recent advances in drug development. Curr Med Chem 2010; 17:2837–2853.

10.

Distinto

Maccioni

Meleddu

. Molecular aspects of the RT/drug interactions. Perspective of dual inhibitors. Curr Pharm Des 2013; 19:1850–1859.

11.

Ellison

Gerton

Vincent

Brown

. An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer. J Biol Chem 1995; 270:3320–3326.

12.

Faure

Calmels

Desjobert

. HIV-1 integrase crosslinked oligomero are active in vitro. Nucleic Acids Res 2005; 33:977–986.

13.

Guiot

Carayon

Delelis

. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J Biol Chem 2006; 281:22707–22719.

14.

De Luca

Antinori

Di Gianbenedetto

. Interpretation systems for genotypic drug resistance of HIV-1. Scand J Infect Dis Suppl 2003; 53:29–34.

15.

Esposito

Craigie

. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical region for protein-DNA interaction. EMBO J 1998; 17:5832–5843.

16.

Miller

Farnet

Bushman

. Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition. J Virol 1997; 71:5382–5390.

17.

Farnet

Haseltine

. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 1991; 65:1910–1915.

18.

Vanegas

Llano

Delgado

Thompson

Peretz

Poeschla

. Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering. J Cell Sci 2005; 118:1733–1743.

19.

Rice

Craigie

Davies

. Retroviral integrases and their cousins. Curr Opin Struct Biol 1996; 6:76–83.

20.

Polard

Chandler

. Bacterial transposases and retroviral integrases. Mol Microbiol 1995; 15:13–23.

21.

Burke

Sanyal

Bruner

. Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase. J Biol Chem 1992; 267:9639–9644.

22.

Lee

Xiao

Knutson

Lewis

Han

. Zn²⁺ promotes the self-association of HIV-1 integrase in vitro. Biochemistry 1997; 36:173–180.

23.

Zheng

Jenkins

Craigie

. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci U S A 1996; 93:13659–13664.

24.

Bouiac-Bertoia

Dvorin

Fouchier

. HIV-1 infection require a functional integrase NLS. Mol Cell 2001; 7:1025–1035.

25.

Berthoux

Sebastian

Muesing

Luban

. The role of lysine 186 in HIV-1 integrase multimerization. Virology 2007; 364:227–236.

26.

Cherepanov

Maertens

Proost

. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 2003; 278:372–381.

27.

Ciuffi

Llano

Poeschla

. A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med 2005; 11:1287–1289.

28.

Wang

Ling

Yang

Craigie

. Structure of a two-domain fragment of HIV-1 integrase: Implications for domain organization in the intact protein. EMBO J 2001; 20:7333–7343.

29.

Llano

Saenz

Meehan

. An essential role for LEDGF/p75 in HIV integration. Science 2006; 314:461–464.

30.

Engelman

Hikman

Craigie

. The core and carboxyl-terminal domains of integrase protein of HIV-1 each contribute to non-specific DNA binding. J Virol 1994; 68:5911–5917.

31.

Lutzke

Plasterk

. Structure-based mutational analysis of the C-terminal DNA binding domain of HIV-1 integrase: Critical residues for protein oligomerization and DNA binding. J Virol 1998; 72:4841–4848.

32.

Lutzke

Vink

Plasterk

. Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res 1994; 22:4125–4131.

33.

Vink

Oude Groeneger

Plasterk

. Identification of the catalytic and DNA-binding region of the HIV-1 integrase protein. Nucleic Acids Res 1993; 21:1419–1425.

34.

Engelman

Mizuuchi

Craigie

. HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA transter. Cell 1991; 67:1211–1221.

35.

Mulder

Chakrabarti

Muesing

. Interaction of HIV-1 integrase with DNA repair protein hRad18. J Biol Chem 2002; 277:27489–27493.

36.

Yoder

Bushman

. Repair of gaps in retroviral DNA integration intermediates. J Virol 2000; 74:11191–11200.

37.

Hare

Gupta

Valkov

Engelman

Cherepanov

. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010; 464:232–236.

38.

Esposito

Corona

Tramontano

. HIV-1 reverse transcriptase still remains a new drug target: Structure, function, classical inhibitors, and new inhibitors with innovative mechanism of actions. Mol Biol Intern 2012; 2012:586401.

39.

Kohlstaedt

Wang

Friedman

Rice

Steitz

. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexes with an inhibitor. Science 1992; 256:1783–1790.

40.

Jacobo-Molina

Ding

Nanni

. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A 1993; 90:6320–6324.

41.

Nowotny

Gaidamakov

Crouch

Yang

. Crystal structures of RNase H bound to an RNA/DNA hybrid: Substrate specificity and metal-dependent catalysis. Cell 2005; 121:1005–1016.

42.

Beilhartz

Götte

. HIV-1 ribonuclease H: Structure, catalytic mechanism and inhibitors. Viruses 2010; 2:900–926.

43.

Mizrahi

Usdin

Harington

Dudding

. Site-directed mutagenesis of the conserved Asp-443 and Asp-498 carboxy-terminal residues of HIV-1 reverse transcriptase. Nucleic Acids Res 1990; 18:5359–5363.

44.

Hazuda

Felock

Witmer

. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646–650.

45.

Marchand

Zhang

Pais

. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem 2002; 277:12596–12603.

46.

Reinke

Lee

Robinson

. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo acid. Antimicrob Agents Chemother 2002; 46:3301–3303.

47.

Goldgur

Craigie

Cohen

. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc Natl Acad Sci U S A 1999; 96:13040–13043.

48.

Billich

. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs 2003; 4:206–209.

49.

Anthony

. HIV-1 integrase: A target for new AIDS chemotherapeutics. Curr Top Med Chem 2004; 4:979–990.

50.

Burger

. Raltergravir: A review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin Drug Metab Toxicol 2010; 6:1151–1160.

51.

Krishnan

Naraharisetty

Hare

Cherepanov

Engelman

. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A 2010; 107:15910–15915.

52.

Métifiot

Marchand

Maddali

Pommier

. Resistance to integrase inhibitors. Viruses 2010; 2:1347–1366.

53.

Pendri

Meanwell

Peese

Walker

. New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Expert Opin Ther Pat 2011; 21:1173–1189.

54.

De Jesus

. Antiretroviral agents in development. (Updated 30 March 2006. Accessed 10 August 2013.) Available from http://www.thebody.com/content/art1352.html.

55.

Blanco

Varghese

Rhee

Gatell

Shafer

. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203:1204–1214.

56.

Shimura

Kodama

Sakagami

. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor eltvitegravir (JTK-303/SG-9137). J Virol 2008; 82:764–774.

57.

Fantauzzi

Turriziani

Mezzaroma

. Potential benefit of dolutegravir once daily: Efficacy and safety. HIV AIDS (Auckl) 2013; 5:29–40.

58.

Al-Mawsawi

Al-Safi

Neamati

. Anti-infectives: Clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs 2008; 13:213–225.

59.

Goethals

van Ginderen

Vos

. Resistance to raltegavir highlights integrase mutations at codon 148 in conferring cross-resistance to a second- generation HIV-1 integrase inhibitor. Antiviral Res 2011; 91:167–176.

60.

Bar-Magen

Sloan

Donahue

. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010; 84:9210–9216.

61.

Summa

Petrocchi

Matassa

. 4, 5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J Med Chem 2006; 49:6646–6649.

62.

Pace

Di Francesco

Gardelli

. Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. J Med Chem 2007; 50:2225–2239.

63.

Petrocchi

Koch

Matassa

Pacini

Stillmock

Summa

. From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety. Bioorg Med Chem Lett 2007; 17:350–353.

64.

Dayam

Al-Mawsawi

Neamati

. Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. Bioorg Med Chem Lett 2007; 17:6155–6159.

65.

Wang

. Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase. Bioorg Med Chem Lett 2011; 21:6724–6727.

66.

Pendri

Troyer

Sofia

. Solid phase synthesis of a novel pyrrolidinedione analogs as potent HIV-1 integrase inhibitors. J Comb Chem 2010; 12:84–90.

67.

Sriram

Yogeeswari

Senchani

Banerjee

. Newer tetracycline derivatives: Synthesis, anti- HIV, antimycobacterial activities and inhibition of HIV-1 integrase. Bioorg Med Chem Lett 2007; 17:2372–2375.

68.

Zouhiri

Mouscadet

Mekouar

. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J Med Chem 2000; 43:1533–1540.

69.

Ouali

Laboulais

Leh

. Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. J Med Chem 2000; 43:1949–1957.

70.

Yoo

Lee

Park

Chung

Lee

. Synthesis of styrylbenzofuran derivatives as styrylquinoline analogues for HIV-1 integrase inhibitor. Farmaco 2003; 58:1243–1250.

71.

Mouscadet

J-F

Desmaele

. Chemistry and structure-activity relationship of the styrylquinoline-type HIV integrase inhibitors. Molecules 2010; 15:3048–3078.

72.

Zhao

Semenova

. 2,3-Dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors. J Med Chem 2008; 51:251–259.

73.

Zhao

Maddali

Smith

. 6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2012; 22:7309–7313.

74.

Brzozowski

Saczewski

Slawinski

Sanchez

Neamati

. Synthesis and anti-HIV-1 integrase activities of 3-aroyl-2,3-dihydro-1,1-dioxo-1,4,2-benzodithiazines. Eur J Med Chem 2009; 44:190–196.

75.

Bransová

Brtko

Uher

Novotny

. Antileukemic activity of 4-pyranone derivatives. Int J Biochem Cell Biol 1995; 27:701–706.

76.

Gupta

Babu

Kaw

. Quantitative structure-activity relationships of some HIV-protease inhibitors. J Enzym Inhib 1999; 14:109–123.

77.

Ramkumar

Tambov

Gundla

Manaev

Yarovenko

. Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase Inhibitors. Bioorg Med Chem 2008; 16:8988–8998.

78.

Hadi

Koh

Y-H

Sanchez

Barrios

Neamati

Jung

. Development of the next generation of HIV-1 integrase inhibitors: Pyrazolone as a novel inhibitor scaffold. Bioorg Med Chem Lett 2010; 20:6854–6857.

79.

Zhao

Maddali

Metifiot

. Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors. Chem Biol Drug Des 2012; 79:157–165.

80.

Johns

Weatherhead

Allen

Thompson

Garvey

Foster

. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. Bioorg Med Chem Lett 2009; 19:1802–1806.

81.

Korolev

Kondrashina

Druzhilovsky

. Structural-functional analysis of 2,1,3-benzoxadiazoles and their N-oxides as HIV-1 integrase inhibitors. Acta Naturae 2013; 5:63–72.

82.

Maurin

Lion

Bailly

. New 2-arylnaphthalenediols and triol inhibitors of HIV-1 integrase – discovery of a new polyhydroxylated antiviral agent. Bioorg Med Chem 2010; 18:5194–5201.

83.

Parkes

KEB

Ermert

Fässler

. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J Med Chem 2003; 46:1153–1164.

84.

Klumpp

Hang

Rajendran

. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res 2003; 31:6852–6859.

85.

Hang

Rajendran

Yang

. Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem Biophys Res Commun 2004; 317:321–329.

86.

Billamboz

Bailly

Barreca

. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J Med Chem 2008; 51:7717–7730.

87.

Billamboz

Bailly

Lion

. Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: Discovery of a novel selective inhibitor of the ribonuclease H function. J Med Chem 2011; 54:1812–1824.

88.

Tomassini

Selnick

Davies

. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 1994; 38:2827–2837.

89.

Shaw-Reid

Munshi

Graham

. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem 2003; 278:2777–2780.

90.

Klumpp

Mirzadegan

. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr Pharm Des 2006; 12:1909–1922.

91.

Shaw-Reid

Feuston

Munshi

. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry 2005; 44:1595–1606.

92.

Costi

Di Santo

Artico

. 2,6-Bis (3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: Novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. Bioorg Med Chem 2004; 12:199–215.

93.

Costi

Di Santo

Artico

. 6-Aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays. Bioorg Med Chem Lett 2004; 14:1745–1749.

94.

Tramontano

Esposito

Badas

Di Santo

Costi

La Colla

. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res 2005; 65:117–124.

95.

Budihas

Gorshkova

Gaidamakov

. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res 2005; 33:1249–1256.

96.

Semenova

Johnson

Marchand

Davis

Yarchoan

Pommier

. Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by alpha-hydroxytropolones. Mol Pharmacol 2006; 69:1454–1460.

97.

Beilhartz

Wendeler

Baichoo

Rausch

Le Grice

Gotte

. HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: Implications for RNase H inhibition. J Mol Biol 2009; 388:462–474.

98.

Himmel

Maegley

Pauly

. Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure 2009; 17:1625–1635.

99.

Didierjean

Isel

Querré

. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H and integrase activities byhydroxytropolones. Antimicrob Agents Chemother 2005; 49:4884–4894.

100.

Hazuda

Anthony

Gomez

. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A 2004; 101:11233–11238.

101.

Yan

Prasad

. Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol 2010; 84:7625–7633.

102.

Williams

Staas

Venkatraman

. Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorg Med Chem Lett 2010; 20:6754–6757.

103.

Kirschberg

Balakrishnan

Squires

. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: Design, biochemical activity, and structural information. J Med Chem 2009; 52:5781–5784.

104.

Lansdon

Liu

Leavitt

. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob Agents Chemother 2011; 55:2905–2915.

105.

Fuji

Urano

Futahashi

. Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase. J Med Chem 2009; 52:1380–1387.

106.

Yanagita

Urano

Matsumoto

. Structural and biochemical study on the inhibitory activity of derivatives of 5-nitro-furan-2-carboxylic acid for RNase H function of HIV-1 reverse transcriptase. Bioorg Med Chem 2011; 19:816–825.

107.

Suchaud

Bailly

Lion

. Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity. Bioorg Med Chem Lett 2012; 22:3988–3992.

108.

Di Grandi

Olson

Prashad

. Small molecule inhibitors of HIV RT Ribonuclease H. Bioorg Med Chem Lett 2010; 20:398–402.

109.

Lapkouski

Tian

Miller

Le Grice

SFJ

Yang

. Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation. Nat Struct Mol Biol 2013; 20:230–236.